Company research
Tempest Therapeutics, Inc.
CIK 1544227Updated Nov 13, 2026
SecurityTPST · NASDAQ · equity
Name history
Millendo Therapeutics, Inc. · through Jul 1, 2021OvaScience, Inc. · through Dec 6, 2018
TPST price & chart
Loading TradingView…
NASDAQ:TPST on TradingView ↗About the company
We are a clinical-stage biotechnology company advancing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, including our lead program, TPST-4003, a dual-targeting CD19/B-cell maturation antigen (“BCMA”) in vivo CAR-T product candidate, which we are developing for indications in immunology and oncology. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a dual-targeting CAR-T platform, which included product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/BCMA CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma and the rare disease, POEMS syndrome.
In the news
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 17,129,000Source | 33,836,000Source | 9,633,000Source | 24,484,000Source | 42,169,000Source | 10,748,000Source | 32,164,000Source | 44,378,000Source | 16,931,000Source | 41,488,000Source | 51,603,000Source | 46,089,000Source |
| Property, Plant and Equipment, NetUSD | 681,000Source | 932,000Source | 486,000Source | 748,000Source | 1,014,000Source | 545,000Source | 817,000Source | 920,000Source | 605,000Source | 886,000Source | 840,000Source | 1,060,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,514,000Source | 22,116,000Source | 779,000Source | 14,280,000Source | 31,124,000Source | 1,805,000Source | 21,511,000Source | 32,326,000Source | 7,707,000Source | 30,268,000Source | 39,230,000Source | 31,230,000Source |
| Assets, CurrentUSD | 8,104,000Source | 23,552,000Source | 1,697,000Source | 15,103,000Source | 31,548,000Source | 2,446,000Source | 22,433,000Source | 33,497,000Source | 8,269,000Source | 31,474,000Source | 40,363,000Source | 32,950,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 590,000Source | 1,436,000Source | 918,000Source | 823,000Source | 424,000Source | 641,000Source | 922,000Source | 1,171,000Source | 562,000Source | 1,206,000Source | 1,133,000Source | 1,270,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,825,000Source | 8,904,000Source | 6,949,000Source | 8,104,000Source | 9,159,000Source | 7,248,000Source | 8,376,000Source | 9,513,000Source | 7,540,000Source | 8,643,000Source | 9,952,000Source | 11,650,000Source |
| Other Assets, NoncurrentUSD | 519,000Source | 448,000Source | 501,000Source | 529,000Source | 448,000Source | 509,000Source | 538,000Source | 448,000Source | 517,000Source | 485,000Source | 448,000Source | 429,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 10,783,000Source | 22,379,000Source | 10,723,000Source | 14,701,000Source | 25,230,000Source | 9,926,000Source | 21,031,000Source | 23,746,000Source | 10,263,000Source | 22,362,000Source | 24,835,000Source | 27,978,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 4,000Source | 27,000Source | 16,000Source | 4,000Source | 24,000Source | 14,000Source | 4,000Source | 22,000Source | 5,000Source | 44,000Source | 22,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 235,689,000Source | 204,723,000Source | 274,210,000Source | 235,615,000Source | 199,652,000Source | 270,880,000Source | 229,095,000Source | 193,777,000Source | 240,031,000Source | 226,188,000Source | 192,009,000Source | 153,872,000Source |
| Retained Earnings (Accumulated Deficit)USD | -229,347,000Source | -193,293,000Source | -275,316,000Source | -225,836,000Source | -182,737,000Source | -270,072,000Source | -217,966,000Source | -173,167,000Source | -233,368,000Source | -207,106,000Source | -165,263,000Source | -135,772,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,346,000Source | 11,457,000Source | -1,090,000Source | 9,783,000Source | 16,939,000Source | 822,000Source | 11,133,000Source | 20,632,000Source | 6,668,000Source | 19,126,000Source | 26,768,000Source | 18,111,000Source |
| Liabilities and EquityUSD | 17,129,000Source | 33,836,000Source | 9,633,000Source | 24,484,000Source | 42,169,000Source | 10,748,000Source | 32,164,000Source | 44,378,000Source | 16,931,000Source | 41,488,000Source | 51,603,000Source | 46,089,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,525,000Source | 13,973,000Source | 4,450,000Source | 7,141,000Source | 14,559,000Source | 3,311,000Source | 13,177,000Source | 10,691,000Source | 3,314,000Source | 14,220,000Source | 9,411,000Source | 7,277,000Source |
| Operating Lease, Liability, CurrentUSD | 1,147,000Source | 828,000Source | 1,287,000Source | 1,103,000Source | 939,000Source | 1,239,000Source | 1,061,000Source | 858,000Source | 1,192,000Source | 869,000Source | 952,000Source | 1,413,000Source |
| Accounts Payable, CurrentUSD | 922,000Source | 1,697,000Source | 1,995,000Source | 4,716,000Source | 1,357,000Source | 585,000Source | 2,187,000Source | 1,051,000Source | 1,038,000Source | 2,450,000Source | 845,000Source | 1,108,000Source |
| Operating Lease, Liability, NoncurrentUSD | 7,258,000Source | 8,406,000Source | 6,273,000Source | 7,560,000Source | 8,663,000Source | 6,615,000Source | 7,854,000Source | 8,915,000Source | 6,949,000Source | 8,142,000Source | 9,160,000Source | 10,330,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,353,000Source | 1,459,000Source | 715,000Source | 1,221,000Source | 2,379,000Source | 1,162,000Source | 4,985,000Source | 1,524,000Source | 937,000Source | 2,726,000Source | 1,673,000Source | 2,961,000Source |
| Long-term DebtUSD | — | 8,500,000Source | — | — | 10,700,000Source | — | 4,200,000Source | 10,600,000Source | — | 6,400,000Source | 10,500,000Source | 10,400,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 8,504,000Source | — | 0Source | 8,645,000Source | — | 4,190,000Source | 6,458,000Source | 0Source | 6,354,000Source | 4,285,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | — | — | 2,008,000Source | — | — | 4,140,000Source | — | 0Source | 6,264,000Source | 10,371,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,511,000Source | -10,556,000Source | -5,244,000Source | -7,870,000Source | -27,696,000Source | -10,860,000Source | -26,262,000Source | -41,843,000Source | -29,491,000Source | -35,709,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,598,000Source | -8,036,000Source | -26,820,000Source | -33,027,000Source | -27,357,000Source | -31,072,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | -435,000Source | -170,000Source | -562,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 435,000Source | 170,000Source | 562,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,696,000Source | -721,000Source | 4,259,000Source | 24,500,000Source | 35,602,000Source | 11,403,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 7,957,000Source | 22,911,000Source | 1,222,000Source | 14,723,000Source | 2,248,000Source | 21,954,000Source | 8,150,000Source | 30,711,000Source | 39,673,000Source | 31,598,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 148,000Source | 192,000Source | 1,177,000Source | 1,249,000Source | 1,539,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 61,000Source | 1,334,000Source | -117,000Source | 1,092,000Source | 226,000Source | 1,389,000Source | 3,118,000Source | 5,303,000Source | 2,546,000Source | 1,561,000Source |
| DepreciationUSD | — | — | 66,000Source | 98,000Source | 59,000Source | 67,000Source | 60,000Source | 68,000Source | 266,000Source | 389,000Source | 381,000Source | 638,000Source |
| General and Administrative ExpenseUSD | — | — | 3,027,000Source | 2,994,000Source | 3,431,000Source | 4,095,000Source | 5,425,000Source | 3,309,000Source | 13,969,000Source | 13,550,000Source | 11,659,000Source | 12,113,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 329,000Source | 0Source | 46,000Source | 0Source | 161,000Source | 207,000Source | 1,316,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,511,000Source | -10,556,000Source | -5,244,000Source | -7,870,000Source | -27,696,000Source | -10,860,000Source | -26,262,000Source | -41,843,000Source | -29,491,000Source | -35,709,000Source |
| Nonoperating Income (Expense)USD | — | — | 86,000Source | -5,000Source | 6,000Source | 96,000Source | 23,000Source | 76,000Source | 313,000Source | 183,000Source | -334,000Source | -1,069,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 86,000Source | 324,000Source | 6,000Source | 142,000Source | 23,000Source | 237,000Source | 520,000Source | 1,499,000Source | 1,115,000Source | 549,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 1,443,000Source | 6,045,000Source | 28,591,000Source | 35,602,000Source | 8,861,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,597,000Source | -10,551,000Source | -5,250,000Source | -7,966,000Source | -27,719,000Source | -10,936,000Source | -26,575,000Source | -42,026,000Source | -29,157,000Source | -34,640,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 86,000Source | 324,000Source | 6,000Source | 142,000Source | 23,000Source | 237,000Source | 520,000Source | 1,499,000Source | 1,115,000Source | 549,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,511,000Source | -10,556,000Source | -5,244,000Source | -7,870,000Source | -27,696,000Source | -10,860,000Source | -26,262,000Source | -41,843,000Source | -29,491,000Source | -35,709,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.79Source | -5.32Source | -0.34Source | -2.07Source | -2.53Source | -3.16Source | -6.33Source | -1.5Source | -1.91Source | -3.09Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.79Source | -5.32Source | -0.34Source | -2.07Source | -2.53Source | -3.16Source | -6.33Source | -1.5Source | -1.91Source | -3.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,440,111Source | 1,985,133Source | 15,223,972Source | 3,802,956Source | 10,931,593Source | 3,437,671Source | 4,149,733Source | 27,901,739Source | 15,416,203Source | 11,548,907Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,440,111Source | 1,985,133Source | 15,223,972Source | 3,802,956Source | 10,931,593Source | 3,437,671Source | 4,149,733Source | 27,901,739Source | 15,416,203Source | 11,548,907Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 329,000Source | 0Source | 46,000Source | 0Source | 161,000Source | 207,000Source | 1,316,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,027,000Source | 2,994,000Source | 3,431,000Source | 4,095,000Source | 5,425,000Source | 3,309,000Source | 13,969,000Source | 13,550,000Source | 11,659,000Source | 12,113,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,449,000Source | 1,618,000Source |
| Nonoperating Income (Expense)USD | — | — | 86,000Source | -5,000Source | 6,000Source | 96,000Source | 23,000Source | 76,000Source | 313,000Source | 183,000Source | -334,000Source | -1,069,000Source |
Offerings
Registration 333-299142
Registration 333-298498
Underwriters: Assumed Average Purchase Price Per Share
Registration 333-297061
Registration 333-294843
Registration 333-294740
Registration 333-292026
Filing attachments
ea031198201ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate -Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and pr…
Read attachment ↗ea030902801ex99-1.htm · 8-K · 2026-10-19
Exhibit 99.1 Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise Brisbane, CA, October 14, 2026 - Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W. Frederick has been appointed to its board of directors. Mr. Frederick brings extensive executive leadershi…
Read attachment ↗ea030674101ex99-1.htm · 8-K · 2026-09-28
Exhibit 99.1 Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors September 23, 2026 Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease,…
Read attachment ↗d185404dex991.htm · 8-K · 2026-09-17
EX-99.1 3 d185404dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform -Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma -Early clinical observations demonstra…
Read attachment ↗d108044dex41.htm · 8-K · 2026-09-15
EX-4.1 2 d108044dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T…
Read attachment ↗d108044dex42.htm · 8-K · 2026-09-15
EX-4.2 3 d108044dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T…
Read attachment ↗